APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Myocardial Infarction Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Myocardial Infarction Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174015280319 December 2025198 pages

Choose your research edition.

Industry ResearchMyocardial Infarction Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Myocardial Infarction Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Myocardial Infarction Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myocardial Infarction Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Myocardial Infarction Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Myocardial Infarction Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Myocardial Infarction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Myocardial Infarction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Myocardial Infarction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Myocardial Infarction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Myocardial Infarction Drug include LegoChem Biosciences, Inc, Lee's Pharmaceutical Holdings Limited, Laboratoires Pierre Fabre SA, Juventas Therapeutics, Inc., Immune Pharmaceuticals Inc., HUYA Bioscience International, LLC, Human Stem Cells Institute, Hemostemix Ltd and FibroGen, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Myocardial Infarction Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Myocardial Infarction Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Myocardial Infarction Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Myocardial Infarction Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Myocardial Infarction Drug Segment by Company

LegoChem Biosciences, Inc

Lee's Pharmaceutical Holdings Limited

Laboratoires Pierre Fabre SA

Juventas Therapeutics, Inc.

Immune Pharmaceuticals Inc.

HUYA Bioscience International, LLC

Human Stem Cells Institute

Hemostemix Ltd

FibroGen, Inc.

Cynata Therapeutics Limited

CSL Limited

Compugen Ltd.

Celyad SA

CellProthera

Capricor Therapeutics, Inc.

Biscayne Pharmaceuticals, Inc.

BioCardia, Inc.

Myocardial Infarction Drug Segment by Type

AMRS-001

ANG-4011

Balixafortide

CAP-1002

Cenderitide

JVS-200

KR-33028

Others

Myocardial Infarction Drug Segment by Application

Research Center

Hospital

Clinic

Myocardial Infarction Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myocardial Infarction Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myocardial Infarction Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myocardial Infarction Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Myocardial Infarction Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Myocardial Infarction Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Myocardial Infarction Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Myocardial Infarction Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Myocardial Infarction Drug Industry Trends Table 2. Myocardial Infarction Drug Industry Drivers Table 3. Myocardial Infarction Drug Industry Opportunities and Challenges Table 4. Myocardial Infarction Drug Industry Restraints Table 5. Global Myocardial Infarction Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Myocardial Infarction Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Myocardial Infarction Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Myocardial Infarction Drug Sales Market Share by Manufacturers Table 9. Global Myocardial Infarction Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Myocardial Infarction Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Myocardial Infarction Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Myocardial Infarction Drug Manufacturers, Product Type & Application Table 13. Global Myocardial Infarction Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Myocardial Infarction Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of AMRS-001 Table 17. Major Manufacturers of ANG-4011 Table 18. Major Manufacturers of Balixafortide Table 19. Major Manufacturers of CAP-1002 Table 20. Major Manufacturers of Cenderitide Table 21. Major Manufacturers of JVS-200 Table 22. Major Manufacturers of KR-33028 Table 23. Major Manufacturers of Others Table 24. Global Myocardial Infarction Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Myocardial Infarction Drug Sales by Type (2021-2026) & (W Units) Table 26. Global Myocardial Infarction Drug Sales by Type (2027-2032) & (W Units) Table 27. Global Myocardial Infarction Drug Sales Market Share by Type (2021-2026) Table 28. Global Myocardial Infarction Drug Sales Market Share by Type (2027-2032) Table 29. Global Myocardial Infarction Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Myocardial Infarction Drug Revenue by Type (2021-2026) & (W Units) Table 31. Global Myocardial Infarction Drug Revenue by Type (2027-2032) & (W Units) Table 32. Global Myocardial Infarction Drug Revenue Market Share by Type (2021-2026) Table 33. Global Myocardial Infarction Drug Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Research Center Table 35. Major Manufacturers of Hospital Table 36. Major Manufacturers of Clinic Table 37. Global Myocardial Infarction Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Myocardial Infarction Drug Sales by Application (2021-2026) & (W Units) Table 39. Global Myocardial Infarction Drug Sales by Application (2027-2032) & (W Units) Table 40. Global Myocardial Infarction Drug Sales Market Share by Application (2021-2026) Table 41. Global Myocardial Infarction Drug Sales Market Share by Application (2027-2032) Table 42. Global Myocardial Infarction Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 43. Global Myocardial Infarction Drug Revenue by Application (2021-2026) & (W Units) Table 44. Global Myocardial Infarction Drug Revenue by Application (2027-2032) & (W Units) Table 45. Global Myocardial Infarction Drug Revenue Market Share by Application (2021-2026) Table 46. Global Myocardial Infarction Drug Revenue Market Share by Application (2027-2032) Table 47. Global Myocardial Infarction Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Myocardial Infarction Drug Sales by Region (2021-2026) & (W Units) Table 49. Global Myocardial Infarction Drug Sales Market Share by Region (2021-2026) Table 50. Global Myocardial Infarction Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 51. Global Myocardial Infarction Drug Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. North America Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 54. North America Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 55. Europe Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Europe Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 57. Europe Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 58. Asia Pacific Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Asia Pacific Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 60. Asia Pacific Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 61. South America, Middle East and Africa Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. South America, Middle East and Africa Myocardial Infarction Drug Sales by Country (2021-2026) & (W Units) Table 63. South America, Middle East and Africa Myocardial Infarction Drug Sales by Country (2027-2032) & (W Units) Table 64. Global Myocardial Infarction Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Myocardial Infarction Drug Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Myocardial Infarction Drug Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Myocardial Infarction Drug Revenue Market Share by Region (2021-2026) Table 68. Global Myocardial Infarction Drug Revenue Market Share by Region (2027-2032) Table 69. LegoChem Biosciences, Inc Company Information Table 70. LegoChem Biosciences, Inc Business Overview Table 71. LegoChem Biosciences, Inc Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. LegoChem Biosciences, Inc Myocardial Infarction Drug Product Portfolio Table 73. LegoChem Biosciences, Inc Recent Development Table 74. Lee's Pharmaceutical Holdings Limited Company Information Table 75. Lee's Pharmaceutical Holdings Limited Business Overview Table 76. Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Product Portfolio Table 78. Lee's Pharmaceutical Holdings Limited Recent Development Table 79. Laboratoires Pierre Fabre SA Company Information Table 80. Laboratoires Pierre Fabre SA Business Overview Table 81. Laboratoires Pierre Fabre SA Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Laboratoires Pierre Fabre SA Myocardial Infarction Drug Product Portfolio Table 83. Laboratoires Pierre Fabre SA Recent Development Table 84. Juventas Therapeutics, Inc. Company Information Table 85. Juventas Therapeutics, Inc. Business Overview Table 86. Juventas Therapeutics, Inc. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Juventas Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio Table 88. Juventas Therapeutics, Inc. Recent Development Table 89. Immune Pharmaceuticals Inc. Company Information Table 90. Immune Pharmaceuticals Inc. Business Overview Table 91. Immune Pharmaceuticals Inc. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Immune Pharmaceuticals Inc. Myocardial Infarction Drug Product Portfolio Table 93. Immune Pharmaceuticals Inc. Recent Development Table 94. HUYA Bioscience International, LLC Company Information Table 95. HUYA Bioscience International, LLC Business Overview Table 96. HUYA Bioscience International, LLC Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. HUYA Bioscience International, LLC Myocardial Infarction Drug Product Portfolio Table 98. HUYA Bioscience International, LLC Recent Development Table 99. Human Stem Cells Institute Company Information Table 100. Human Stem Cells Institute Business Overview Table 101. Human Stem Cells Institute Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Human Stem Cells Institute Myocardial Infarction Drug Product Portfolio Table 103. Human Stem Cells Institute Recent Development Table 104. Hemostemix Ltd Company Information Table 105. Hemostemix Ltd Business Overview Table 106. Hemostemix Ltd Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Hemostemix Ltd Myocardial Infarction Drug Product Portfolio Table 108. Hemostemix Ltd Recent Development Table 109. FibroGen, Inc. Company Information Table 110. FibroGen, Inc. Business Overview Table 111. FibroGen, Inc. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. FibroGen, Inc. Myocardial Infarction Drug Product Portfolio Table 113. FibroGen, Inc. Recent Development Table 114. Cynata Therapeutics Limited Company Information Table 115. Cynata Therapeutics Limited Business Overview Table 116. Cynata Therapeutics Limited Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Cynata Therapeutics Limited Myocardial Infarction Drug Product Portfolio Table 118. Cynata Therapeutics Limited Recent Development Table 119. CSL Limited Company Information Table 120. CSL Limited Business Overview Table 121. CSL Limited Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. CSL Limited Myocardial Infarction Drug Product Portfolio Table 123. CSL Limited Recent Development Table 124. Compugen Ltd. Company Information Table 125. Compugen Ltd. Business Overview Table 126. Compugen Ltd. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Compugen Ltd. Myocardial Infarction Drug Product Portfolio Table 128. Compugen Ltd. Recent Development Table 129. Celyad SA Company Information Table 130. Celyad SA Business Overview Table 131. Celyad SA Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Celyad SA Myocardial Infarction Drug Product Portfolio Table 133. Celyad SA Recent Development Table 134. CellProthera Company Information Table 135. CellProthera Business Overview Table 136. CellProthera Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. CellProthera Myocardial Infarction Drug Product Portfolio Table 138. CellProthera Recent Development Table 139. Capricor Therapeutics, Inc. Company Information Table 140. Capricor Therapeutics, Inc. Business Overview Table 141. Capricor Therapeutics, Inc. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Capricor Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio Table 143. Capricor Therapeutics, Inc. Recent Development Table 144. Biscayne Pharmaceuticals, Inc. Company Information Table 145. Biscayne Pharmaceuticals, Inc. Business Overview Table 146. Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Product Portfolio Table 148. Biscayne Pharmaceuticals, Inc. Recent Development Table 149. BioCardia, Inc. Company Information Table 150. BioCardia, Inc. Business Overview Table 151. BioCardia, Inc. Myocardial Infarction Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. BioCardia, Inc. Myocardial Infarction Drug Product Portfolio Table 153. BioCardia, Inc. Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Myocardial Infarction Drug Distributors List Table 157. Myocardial Infarction Drug Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Myocardial Infarction Drug Product Image Figure 2. Global Myocardial Infarction Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Myocardial Infarction Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Myocardial Infarction Drug Sales (2021-2032) & (W Units) Figure 5. Global Myocardial Infarction Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Myocardial Infarction Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. AMRS-001 Image Figure 9. ANG-4011 Image Figure 10. Balixafortide Image Figure 11. CAP-1002 Image Figure 12. Cenderitide Image Figure 13. JVS-200 Image Figure 14. KR-33028 Image Figure 15. Others Image Figure 16. Global Myocardial Infarction Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Myocardial Infarction Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Myocardial Infarction Drug Sales Market Share by Type (2021-2032) Figure 19. Global Myocardial Infarction Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Myocardial Infarction Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Myocardial Infarction Drug Revenue Market Share by Type (2021-2032) Figure 22. Research Center Image Figure 23. Hospital Image Figure 24. Clinic Image Figure 25. Global Myocardial Infarction Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Myocardial Infarction Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Myocardial Infarction Drug Sales Market Share by Application (2021-2032) Figure 28. Global Myocardial Infarction Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 29. Global Myocardial Infarction Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Myocardial Infarction Drug Revenue Market Share by Application (2021-2032) Figure 31. North America Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. North America Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 33. U.S. Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Canada Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Mexico Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Europe Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 38. Germany Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. France Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. U.K. Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Italy Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Netherlands Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Asia Pacific Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 45. China Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Japan Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South Korea Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Southeast Asia Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. India Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Australia Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South America, Middle East and Africa Myocardial Infarction Drug Sales Market Share by Country (2021-2032) Figure 53. Brazil Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. South Africa Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Saudi Arabia Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Turkey Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Argentina Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. UAE Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Egypt Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Chile Myocardial Infarction Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Global Myocardial Infarction Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Myocardial Infarction Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Myocardial Infarction Drug Revenue (2021-2032) & (US$ Million) Figure 64. North America Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Myocardial Infarction Drug Revenue (2021-2032) & (US$ Million) Figure 66. Europe Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Myocardial Infarction Drug Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Myocardial Infarction Drug Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Myocardial Infarction Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Myocardial Infarction Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • AMRS-001
  • ANG-4011
  • Balixafortide
  • CAP-1002
  • Cenderitide
  • JVS-200
  • KR-33028
  • Others
Applications
  • Research Center
  • Hospital
  • Clinic
Companies covered
  • LegoChem Biosciences, Inc
  • Lee's Pharmaceutical Holdings Limited
  • Laboratoires Pierre Fabre SA
  • Juventas Therapeutics, Inc.
  • Immune Pharmaceuticals Inc.
  • HUYA Bioscience International, LLC
  • Human Stem Cells Institute
  • Hemostemix Ltd
  • FibroGen, Inc.
  • Cynata Therapeutics Limited
  • CSL Limited
  • Compugen Ltd.
  • Celyad SA
  • CellProthera
  • Capricor Therapeutics, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • BioCardia, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Myocardial Infarction Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Myocardial Infarction Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Myocardial Infarction Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Myocardial Infarction Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Myocardial Infarction Drug Market Dynamics
  1. 2.1 Myocardial Infarction Drug Industry Trends
  2. 2.2 Myocardial Infarction Drug Industry Drivers
  3. 2.3 Myocardial Infarction Drug Industry Opportunities and Challenges
  4. 2.4 Myocardial Infarction Drug Industry Restraints
3 Myocardial Infarction Drug Market by Manufacturers
  1. 3.1 Global Myocardial Infarction Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Myocardial Infarction Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Myocardial Infarction Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Myocardial Infarction Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Myocardial Infarction Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Myocardial Infarction Drug Manufacturers, Product Type & Application
  7. 3.7 Global Myocardial Infarction Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Myocardial Infarction Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Myocardial Infarction Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Myocardial Infarction Drug Tier 1, Tier 2, and Tier 3
4 Myocardial Infarction Drug Market by Type
  1. 4.1 Myocardial Infarction Drug Type Introduction
  2. 4.1.1 AMRS-001
  3. 4.1.2 ANG-4011
  4. 4.1.3 Balixafortide
  5. 4.1.4 CAP-1002
  6. 4.1.5 Cenderitide
  7. 4.1.6 JVS-200
  8. 4.1.7 KR-33028
  9. 4.1.8 Others
  10. 4.2 Global Myocardial Infarction Drug Sales by Type
  11. 4.2.1 Global Myocardial Infarction Drug Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Myocardial Infarction Drug Sales by Type (2021-2032)
  13. 4.2.3 Global Myocardial Infarction Drug Sales Market Share by Type (2021-2032)
  14. 4.3 Global Myocardial Infarction Drug Revenue by Type
  15. 4.3.1 Global Myocardial Infarction Drug Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Myocardial Infarction Drug Revenue by Type (2021-2032)
  17. 4.3.3 Global Myocardial Infarction Drug Revenue Market Share by Type (2021-2032)
5 Myocardial Infarction Drug Market by Application
  1. 5.1 Myocardial Infarction Drug Application Introduction
  2. 5.1.1 Research Center
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Myocardial Infarction Drug Sales by Application
  6. 5.2.1 Global Myocardial Infarction Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Myocardial Infarction Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Myocardial Infarction Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Myocardial Infarction Drug Revenue by Application
  10. 5.3.1 Global Myocardial Infarction Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Myocardial Infarction Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Myocardial Infarction Drug Revenue Market Share by Application (2021-2032)
6 Global Myocardial Infarction Drug Sales by Region
  1. 6.1 Global Myocardial Infarction Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Myocardial Infarction Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Myocardial Infarction Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Myocardial Infarction Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Myocardial Infarction Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Myocardial Infarction Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Myocardial Infarction Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Myocardial Infarction Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Myocardial Infarction Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Myocardial Infarction Drug Revenue by Region
  1. 7.1 Global Myocardial Infarction Drug Revenue by Region
  2. 7.1.1 Global Myocardial Infarction Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Myocardial Infarction Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Myocardial Infarction Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Myocardial Infarction Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Myocardial Infarction Drug Revenue (2021-2032)
  8. 7.2.2 North America Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Myocardial Infarction Drug Revenue (2021-2032)
  11. 7.3.2 Europe Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Myocardial Infarction Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Myocardial Infarction Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Myocardial Infarction Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 LegoChem Biosciences, Inc
  2. 8.1.1 LegoChem Biosciences, Inc Company Information
  3. 8.1.2 LegoChem Biosciences, Inc Business Overview
  4. 8.1.3 LegoChem Biosciences, Inc Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 LegoChem Biosciences, Inc Myocardial Infarction Drug Product Portfolio
  6. 8.1.5 LegoChem Biosciences, Inc Recent Developments
  7. 8.2 Lee's Pharmaceutical Holdings Limited
  8. 8.2.1 Lee's Pharmaceutical Holdings Limited Company Information
  9. 8.2.2 Lee's Pharmaceutical Holdings Limited Business Overview
  10. 8.2.3 Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lee's Pharmaceutical Holdings Limited Myocardial Infarction Drug Product Portfolio
  12. 8.2.5 Lee's Pharmaceutical Holdings Limited Recent Developments
  13. 8.3 Laboratoires Pierre Fabre SA
  14. 8.3.1 Laboratoires Pierre Fabre SA Company Information
  15. 8.3.2 Laboratoires Pierre Fabre SA Business Overview
  16. 8.3.3 Laboratoires Pierre Fabre SA Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Laboratoires Pierre Fabre SA Myocardial Infarction Drug Product Portfolio
  18. 8.3.5 Laboratoires Pierre Fabre SA Recent Developments
  19. 8.4 Juventas Therapeutics, Inc.
  20. 8.4.1 Juventas Therapeutics, Inc. Company Information
  21. 8.4.2 Juventas Therapeutics, Inc. Business Overview
  22. 8.4.3 Juventas Therapeutics, Inc. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Juventas Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio
  24. 8.4.5 Juventas Therapeutics, Inc. Recent Developments
  25. 8.5 Immune Pharmaceuticals Inc.
  26. 8.5.1 Immune Pharmaceuticals Inc. Company Information
  27. 8.5.2 Immune Pharmaceuticals Inc. Business Overview
  28. 8.5.3 Immune Pharmaceuticals Inc. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Immune Pharmaceuticals Inc. Myocardial Infarction Drug Product Portfolio
  30. 8.5.5 Immune Pharmaceuticals Inc. Recent Developments
  31. 8.6 HUYA Bioscience International, LLC
  32. 8.6.1 HUYA Bioscience International, LLC Company Information
  33. 8.6.2 HUYA Bioscience International, LLC Business Overview
  34. 8.6.3 HUYA Bioscience International, LLC Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 HUYA Bioscience International, LLC Myocardial Infarction Drug Product Portfolio
  36. 8.6.5 HUYA Bioscience International, LLC Recent Developments
  37. 8.7 Human Stem Cells Institute
  38. 8.7.1 Human Stem Cells Institute Company Information
  39. 8.7.2 Human Stem Cells Institute Business Overview
  40. 8.7.3 Human Stem Cells Institute Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Human Stem Cells Institute Myocardial Infarction Drug Product Portfolio
  42. 8.7.5 Human Stem Cells Institute Recent Developments
  43. 8.8 Hemostemix Ltd
  44. 8.8.1 Hemostemix Ltd Company Information
  45. 8.8.2 Hemostemix Ltd Business Overview
  46. 8.8.3 Hemostemix Ltd Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hemostemix Ltd Myocardial Infarction Drug Product Portfolio
  48. 8.8.5 Hemostemix Ltd Recent Developments
  49. 8.9 FibroGen, Inc.
  50. 8.9.1 FibroGen, Inc. Company Information
  51. 8.9.2 FibroGen, Inc. Business Overview
  52. 8.9.3 FibroGen, Inc. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 FibroGen, Inc. Myocardial Infarction Drug Product Portfolio
  54. 8.9.5 FibroGen, Inc. Recent Developments
  55. 8.10 Cynata Therapeutics Limited
  56. 8.10.1 Cynata Therapeutics Limited Company Information
  57. 8.10.2 Cynata Therapeutics Limited Business Overview
  58. 8.10.3 Cynata Therapeutics Limited Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Cynata Therapeutics Limited Myocardial Infarction Drug Product Portfolio
  60. 8.10.5 Cynata Therapeutics Limited Recent Developments
  61. 8.11 CSL Limited
  62. 8.11.1 CSL Limited Company Information
  63. 8.11.2 CSL Limited Business Overview
  64. 8.11.3 CSL Limited Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CSL Limited Myocardial Infarction Drug Product Portfolio
  66. 8.11.5 CSL Limited Recent Developments
  67. 8.12 Compugen Ltd.
  68. 8.12.1 Compugen Ltd. Company Information
  69. 8.12.2 Compugen Ltd. Business Overview
  70. 8.12.3 Compugen Ltd. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Compugen Ltd. Myocardial Infarction Drug Product Portfolio
  72. 8.12.5 Compugen Ltd. Recent Developments
  73. 8.13 Celyad SA
  74. 8.13.1 Celyad SA Company Information
  75. 8.13.2 Celyad SA Business Overview
  76. 8.13.3 Celyad SA Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celyad SA Myocardial Infarction Drug Product Portfolio
  78. 8.13.5 Celyad SA Recent Developments
  79. 8.14 CellProthera
  80. 8.14.1 CellProthera Company Information
  81. 8.14.2 CellProthera Business Overview
  82. 8.14.3 CellProthera Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CellProthera Myocardial Infarction Drug Product Portfolio
  84. 8.14.5 CellProthera Recent Developments
  85. 8.15 Capricor Therapeutics, Inc.
  86. 8.15.1 Capricor Therapeutics, Inc. Company Information
  87. 8.15.2 Capricor Therapeutics, Inc. Business Overview
  88. 8.15.3 Capricor Therapeutics, Inc. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Capricor Therapeutics, Inc. Myocardial Infarction Drug Product Portfolio
  90. 8.15.5 Capricor Therapeutics, Inc. Recent Developments
  91. 8.16 Biscayne Pharmaceuticals, Inc.
  92. 8.16.1 Biscayne Pharmaceuticals, Inc. Company Information
  93. 8.16.2 Biscayne Pharmaceuticals, Inc. Business Overview
  94. 8.16.3 Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biscayne Pharmaceuticals, Inc. Myocardial Infarction Drug Product Portfolio
  96. 8.16.5 Biscayne Pharmaceuticals, Inc. Recent Developments
  97. 8.17 BioCardia, Inc.
  98. 8.17.1 BioCardia, Inc. Company Information
  99. 8.17.2 BioCardia, Inc. Business Overview
  100. 8.17.3 BioCardia, Inc. Myocardial Infarction Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 BioCardia, Inc. Myocardial Infarction Drug Product Portfolio
  102. 8.17.5 BioCardia, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Myocardial Infarction Drug Value Chain Analysis
  2. 9.1.1 Myocardial Infarction Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Myocardial Infarction Drug Production Mode & Process
  6. 9.2 Myocardial Infarction Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Myocardial Infarction Drug Distributors
  9. 9.2.3 Myocardial Infarction Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst